Jose is a specialist in viral infectious diseases and in the development of biotechnology applications of viruses, with more than 120 scientific contributions in international journals and numerous licensed patents. He is on the editorial board of several virology and biotechnology journals. José is a graduate and Ph.D from Complutense University of Madrid in Veterinary Medicine and carried out postdoctoral studies in different institutions of USA. Jose served as Research Professor in a Spanish scientific institution and has over 25 years of experience in science management. As entrepreneur, he is co-founder of ALGENEX and LogicBiology.
Claudia has over 20 years of experience in corporate finance, 14 of which have been in the life sciences sector. She currently serves as CFO of Therachon, a Swiss clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for serious rare conditions. Prior to this she served as CFO at TiGenix, a biopharmaceutical company that developed Alofisel, the first allogenic stem cell product to receive marketing authorization for the treatment of perianal fistulas in Crohn's patients, and was acquired by Takeda in 2018. Claudia currently also serves as Venture Partner at Ysios Capital Partners (ES) as well as on the Board of Bone Therapeutics (BE) and Reneuron (UK). She holds a bachelor's degree in economics and a Ph.D. in Business Administration from Bocconi University in Milan.
Roberto is an investor in the healthcare sector, where he has been active for the past decade. Originally part of 3i’s global healthcare team, he later founded Fort Rock Capital, a specialist investor in the space. He is the Managing Partner of VitaTech (lifesciences), based in Luxembourg and active across Europe. He currently sits on the boards of Vasopharm GmbH (Germany, traumatic brain injury), GNS Healthcare (USA, AI and digital health), Medinet (UK, clinical services), amongst others.
Daniel has more than 20 years of experience in the invitro diagnostic sector through the family-owned company Operon SA. For the past 10 years, he has been responsible for Biotori, dedicated to support biotechnology projects.
Nicola has 23 years of M&A and principal investment experience. He is the founder and managing partner of Cleon Capital, an independent advisory and investment company with offices in Madrid and Milan. Prior to founding Cleon, he served as director and partner of the private equity firms Investindustrial and Ergon Capital. Nicola is a board member of 15 companies located in various jurisdictions across Europe.